2023 saw key developments in the biotech industry, with notable breakthroughs in Alzheimer’s disease treatments, obesity management, and cancer therapy. There were also significant strides in artificial intelligence (AI) and mRNA technology. Key highlights include FDA’s approval of the Alzheimer’s treatment, LEQEMBI, developed by Eisai Co. and Biogen Inc., advancements in obesity treatments such as GLP-1 analogues, and gene therapies, the approval of world’s first CRISPR-based therapy, Casgevy, by the UK, and AI-powered drug repurposing.
Laurentian University is facing concerns about the impact of a cyber incident. The university’s officials are working to address the situation and ensure the security